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Abstract
Background: Azathioprine triggers suicidal erythrocyte death or eryptosis, characterized by cell
shrinkage and exposure of phosphatidylserine at the erythrocyte surface. Eryptosis may accelerate
the clearance of Plasmodium-infected erythrocytes. The present study thus explored whether
azathioprine influences eryptosis of Plasmodium-infected erythrocytes, development of parasitaemia
and thus the course of malaria.
Methods: Human erythrocytes were infected in vitro with Plasmodium falciparum (P. falciparum)
(strain BinH) in the absence and presence of azathioprine (0.001 – 10 μM), parasitaemia determined
utilizing Syto16, phosphatidylserine exposure estimated from annexin V-binding and cell volume
from forward scatter in FACS analysis. Mice were infected with Plasmodium berghei (P. berghei)
ANKA by injecting parasitized murine erythrocytes (1 × 106) intraperitoneally. Where indicated
azathioprine (5 mg/kg b.w.) was administered subcutaneously from the eighth day of infection.
Results: In vitro infection of human erythrocytes with P. falciparum increased annexin V-binding and
initially decreased forward scatter, effects significantly augmented by azathioprine. At higher
concentrations azathioprine significantly decreased intraerythrocytic DNA/RNA content (≥ 1 μM)
and in vitro parasitaemia (≥ 1 μM). Administration of azathioprine significantly decreased the
parasitaemia of circulating erythrocytes and increased the survival of P. berghei-infected mice (from
0% to 77% 22 days after infection).
Conclusion: Azathioprine inhibits intraerythrocytic growth of P. falciparum, enhances suicidal
death of infected erythrocytes, decreases parasitaemia and fosters host survival during malaria.
Background
Infection of erythrocytes with Plasmodium falciparum stim-
ulates eryptosis, the suicidal death of erythrocytes [1,2].
Eryptosis is characterized by cell membrane scrambling
leading to phosphatidylserine exposure at the cell surface
[3-7]. Triggers of cell membrane scrambling include
increased cytosolic Ca2+ activity [3,5,6,8] and ceramide
[9]. Ca2+ may enter erythrocytes through Ca2+-permeable
cation channels, which could be activated by osmotic
shock, oxidative stress or energy depletion [8,10-12]. Ca2+
further activates Ca2+-sensitive K+ channels [13,14], lead-
ing to exit of KCl and osmotically obliged water and thus
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to cell shrinkage [15]. Plasmodium infection imposes oxi-
dative stress onto host erythrocytes, which activates Ca2+-
permeable cation channels [16] and, thus, fosters cell
membrane scrambling and phosphatidylserine exposure
at the erythrocyte surface [17]. Sustained increase in
cytosolic Ca2+ similarly stimulates apoptosis of nucleated
cells [18]. As phosphatidylserine-exposing cells are bound
to receptors of macrophages [19,20] and phagocytosed
[21,22], eryptotic cells are rapidly cleared from circulating
blood [23].
During malaria, the clearance of infected erythrocytes
prior to the development of trophozoites [24] may coun-
teract the development of parasitaemia [25]. Along those
lines clearance of ring stage Plasmodium-infected erythro-
cytes is accelerated by sickle-cell trait, beta-thalassaemia-
trait, homozygous Hb-C and G6PD-deficiency, genetic
conditions associated with a relatively mild course of
malaria [7,26-30]. Moreover, iron deficiency [1] and treat-
ment with lead [2], chlorpromazine [31] and cyclosporine
[32] delay the development of parasitaemia and thus fos-
ter the survival of Plasmodium berghei-infected mice, pre-
sumably at least in part by accelerating erythrocyte death.
Erythropoietin, which inhibits the erythrocyte cation
channel [33] has similarly been shown to influence the
course of malaria [34]. Erythropoietin may, however, be
effective through mechanisms other than stimulation of
eryptosis, which is rather inhibited by the hormone [33].
Azathioprine, a widely used immunosuppressive drug
[35-38], has recently been shown to similarly trigger eryp-
tosis [39]. The present study explored whether azathio-
prine accelerates eryptosis of P. falciparum-infected
erythrocytes and whether it influences parasitaemia and
survival during malaria. Azathioprine (6-mercaptopu-
rine) has previously been shown to inhibit a purine phos-
phoribosyltransferase of the parasite and thus to interfere
with in vitro growth of the parasite [40,41]. An effect on
the survival of infected erythrocytes or in vivo efficacy has,
however, not been reported.
Methods
Animals, cells and solutions
Animal experiments were performed according to the Ger-
man animal protection law and approved by the local
authorities (registration number PY 2/06). Experiments
were performed in healthy SV129/J wild type mice (aged
4 months, both male and female). The animals had free
access to standard chow (C1310, Altromin, Lage, Ger-
many) and drinking water. Murine erythrocytes were
drawn from the animals by incision of the tail vein.
Human erythrocytes were drawn from healthy volunteers.
Experiments were performed at 37°C in Ringer solution
containing (in mM) 125 NaCl, 5 KCl, 1 MgSO4, 32
HEPES/NaOH (pH 7.4), 5 glucose, 1 CaCl2. Azathioprine
was added to the NaCl Ringer at final concentrations var-
ying from 0.001 μM to 10 μM (Sigma, Schnelldorf, Ger-
many). For in vitro azathioprine treatment, the final
haematocrit was adjusted to 0.3%.
Determination of phosphatidylserine exposure
FACS analysis was performed as described [8]. After incu-
bation in the presence or absence of azathioprine, suspen-
sions of P. falciparum-infected erythrocytes were stained
with annexin V-APC (BD Biosciences Pharmingen, Hei-
delberg, Germany) and/or with the DNA/RNA specific
dye Syto16 (Molecular Probes, Göttingen, Germany) to
identify phosphatidylserine-exposing and infected eryth-
rocytes, respectively. For annexin V-binding, erythrocytes
were washed, resuspended in annexin V-binding buffer
(Ringer solution containing 5 mM CaCl2. pH 7.4), stained
with annexin V-APC (dilution 1:20), incubated for 20 min
at room temperature, and diluted 1:5 with annexin V-
binding buffer. Syto16 (final concentration of 20 nM) was
added directly to the diluted erythrocyte suspension or co-
incubated in the annexin V-binding buffer. Cells were
analyzed by flow cytometry (FACS-Calibur, BD) in FL-1
for Syto16 (detected at 530 nm) and in FL-4 for annexin
V-APC fluorescence intensity (detected at 660 nm).
In vitro cultivation of Plasmodium falciparum
For infection of human erythrocytes, the human pathogen
P. falciparum strain BinH [42] was grown in vitro [43]. Par-
asites were cultured as described earlier [44,45] at a hae-
matocrit of 2% and a parasitaemia of 2–10% in RPMI
1640 medium supplemented with Albumax II (0.5%;
Gibco, Karlsruhe, Germany) in an atmosphere of 90% N2,
5% CO2, 5% O2.
In vivo proliferation of Plasmodium berghei
For infection of mice, P. berghei ANKA-parasitized murine
erythrocytes (1 × 106) were injected intraperitoneally
[46,47] into wild-type mice. Where indicated, azathio-
prine (5 mg/kg b.w) was administered subcutaneously
from the eighth day of infection. Blood was collected from
the mice starting on the 8th day after infection. Parasitae-
mia was determined by Syto-16 staining in FACS analysis.
In vitro growth assays of P. falciparum-infected human 
erythrocytes
The P. falciparum BinH strain was cultured and synchro-
nized to the ring stage by sorbitol treatment as described
previously [16]. For the in vitro growth assay, synchro-
nized parasitized erythrocytes were aliquoted in 96-well
plates (200 μl aliquots, 1% haematocrit, 0.5–2% parasi-
taemia) and grown for 48 h in the presence or absence of
azathioprine (0.001 μM – 10 μM). The parasitaemia was
assessed at time 0 and after 48 h of culture by flow cytom-
etry. Parasitaemia was defined by the percentage of eryth-Malaria Journal 2009, 8:102 http://www.malariajournal.com/content/8/1/102
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rocytes stained with the DNA/RNA specific fluorescence
dye Syto16.
To estimate DNA/RNA amplification of the intraerythro-
cytic parasite, the culture was ring stage-synchronized,
and re-synchronized after 6 h of culture (to narrow the
developmental parasite stage), aliquoted (200 μl aliquots,
2% haematocrit and 10% parasitaemia) and cultured for
further 16 h in the presence or absence of azathioprine
(0.001 μM – 10 μM). Thereafter, the DNA/RNA amount
of the parasitized erythrocytes was determined by Syto16
fluorescence as a measure of intraerythrocytic parasite
copies.
Statistics
Data are expressed as arithmetic means ± SEM and statis-
tical analysis was made by t-test or ANOVA using Tukey's
test as post hoc test, as appropriate. p < 0.05 was consid-
ered as statistically significant.
Results
To study the in vitro growth of the parasite, P. falciparum-
infected erythrocytes were cultured in healthy human
erythrocytes and synchronized to ring stage by sorbitol
treatment. The initial parasitaemia was 1.3%. Within 48
hours of culture, i.e., after intraerythrocytic amplification,
evasion from the host cell, and invasion into new erythro-
cytes, some 16% of the erythrocytes were infected, while
84% of the erythrocytes remained noninfected (Figure
1A). The percentage of parasitized erythrocytes was
decreased by the presence of azathioprine, an effect reach-
ing statistical significance at ≥ 1 μM azathioprine concen-
tration (Figure 1A). Similarly, the intraerythrocytic DNA
amplification of the parasite was decreased in the pres-
ence of azathioprine, an effect reaching statistical signifi-
cance at ≥ 1 μM azathioprine concentration (Figure 1B).
Together, the data indicate that azathioprine exerts direct
effects on the parasite at concentrations ≥ 1 μM.
To explore whether infection of erythrocytes triggers eryp-
tosis, phosphatidylserine-exposing erythrocytes were
identified by determination of annexin V-binding in FACS
analysis. Prior to infection, the percentage of annexin V-
binding erythrocytes was low (1.25 ± 0.20%, n = 6). Infec-
tion within 24 hours led to a marked increase in annexin
V-binding of both, infected erythrocytes and noninfected
bystander cells (Figure 2). The percentage of annexin V-
binding was more than double as high in infected than in
noninfected erythrocytes (Figure 2), a difference statisti-
cally significant both, in the absence and presence of aza-
thioprine. The phosphatidylserine exposure of infected
erythrocytes was significantly augmented by azathioprine
(Figure 2), an effect observed at 1 μM azathioprine.
Depending on the stage of the parasite development,
infection of erythrocytes decreased (early stages; Figure
3A) or increased (late stages; Figure 3B) erythrocyte for-
ward scatter, indicating that early stages initially decreased
the host cell volume. Subsequently, during later parasite
development, the volume-expanding trophozoites
increased the host cell volume. Azathioprine at concentra-
tions of 5 and 10 μM decreased the forward scatter of late
Effects of azathioprine on intraerythrocytic amplification and  in vitro parasitaemia Figure 1
Effects of azathioprine on intraerythrocytic amplifi-
cation and in vitro parasitaemia. A. In vitro parasitaemia 
with P. falciparum in human erythrocytes as a function of the 
azathioprine concentration (arithmetic means ± SEM, n = 8). 
* indicates significant difference (p ≤ 0.05) from absence of 
azathioprine. B. Intraerythrocytic DNA amplification as a 
function of the azathioprine concentration (arithmetic means 
± SEM, n = 6).
Effects of azathioprine on phosphatidylserine exposure of  infected and noninfected erythrocytes Figure 2
Effects of azathioprine on phosphatidylserine expo-
sure of infected and noninfected erythrocytes. Arith-
metic means ± SEM (n = 12) of annexin V-binding of infected 
(closed bars) and noninfected (open bars) erythrocytes fol-
lowing infection of human erythrocytes with P. falciparum at 0 
μM (left bars) and 1 μM azathioprine. For comparison, the 
percentage of annexin V-binding erythrocytes prior to infec-
tion is shown (grey bar). ### indicates significant difference 
(p ≤ 0.001; paired ANOVA) from noninfected erythrocytes, 
** indicates significant difference (p ≤ 0.01; paired ANOVA) 
from absence of azathioprine.Malaria Journal 2009, 8:102 http://www.malariajournal.com/content/8/1/102
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stage infected erythrocytes, which was probably due to
azathioprine-induced inhibition of intraerythrocytic para-
site development (see Figure 1B). In the early stage of
infection, however, a statistically significant shrinking
effect of azathioprine on infected cells was evident at
lower concentrations of azathioprine (≥ 0.1 μM). In sum-
mary, these experiments indicate that low concentrations
of azathioprine augment eryptosis of the host erythrocyte.
In a last series of experiments, mice were infected with P.
berghei to determine the in vivo efficacy of azathioprine
treatment. The administration of azathioprine (daily
injections of 5 mg/kg b.w. azathioprine subcutaneously)
was initiated 8 days after infection. At this time, parasitae-
mia was less than 5% (Figure 4B). The percentage of
infected erythrocytes gradually increased in both, treated
and untreated mice. The percentage of parasitized erythro-
cytes was lower in azathioprine-treated animals than in
animals without azathioprine treatment, an effect reach-
ing statistical significance between day 17 and day 20 of
infection (Figures 4A and 4B). Accordingly, azathioprine
treatment at least transiently decreased parasitaemia (Fig-
ure 4A, right panels and Figure 4B).
Azathioprine treatment further affected the survival of P.
berghei-infected mice. As illustrated in Figure 4C, all
untreated animals died within 22 days after the infection.
Effects of azathioprine on forward scatter of infected and  noninfected erythrocytes Figure 3
Effects of azathioprine on forward scatter of infected 
and noninfected erythrocytes. A. Normalized forward 
scatter (n = 12) of the early stage-infected erythrocytes 
(closed symbols) and noninfected (open symbols) erythro-
cytes as a function of the azathioprine concentration. * indi-
cates significant difference (p ≤ 0.05; ANOVA) from absence 
of azathioprine, #, ## indicate significant difference (p ≤ 0.05, p 
≤ 0.01; ANOVA) from noninfected erythrocytes. Nonin-
fected erythrocytes and erythrocytes infected with early and 
late parasite stages were defined by background, intermedi-
ate and high staining of the cells with the DNA/RNA-specific 
fluorescence dye Syto16. B. Normalized forward scatter (n = 
12) of late stage-infected erythrocytes (closed symbols) and 
noninfected (open symbols) erythrocytes as a function of the 
azathioprine concentration. * indicates significant difference 
(p ≤ 0.05; ANOVA) from absence of azathioprine.
Parasitaemia and survival of Plasmodium berghei-infected mice Figure 4
Parasitaemia and survival of Plasmodium berghei-
infected mice. A: Original histograms of parasitaemia-
dependent Syto16 fluorescence in untreated animals (upper 
panels) and animals treated from day 8 until day 20 with 5 
mg/kg b.w. of azathioprine s.c. (lower panels) 10 (left panels) 
and 20 (right panels) days after infection with P. berghei. B: 
Arithmetic means ± SEM of parasitaemia in mice without 
treatment (open circles, n = 12) or with 5 mg/kg b.w. of aza-
thioprine s.c. (closed circles, n = 9) as a function of days after 
infection with P. berghei. * indicates significant difference (p ≤ 
0.05; t-test) from the untreated animals. C: Survival of mice 
without treatment (open circles) or with 5 mg/kg b.w. of aza-
thioprine s.c. (closed squares) as a function of days after 
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In contrast, 77% of the azathioprine-treated animals sur-
vived the infection for more than 22 days.
Discussion
The present study unravels a novel effect of azathioprine,
i.e. the favorable influence on the course of malaria. Most
importantly, azathioprine treatment significantly
enhances the percentage of surviving animals after infec-
tion with P. berghei. As shown previously, without treat-
ment, the infection of mice with P. berghei is followed by
an invariably lethal course of malaria within 22 days [46].
In contrast, most of the mice treated with azathioprine
survived the infection for 22 days.
Several mechanisms may contribute to the efficacy of aza-
thioprine. In theory, the effect of azathioprine could have
been due to its immune-suppressing potency [35-38].
However, it is not likely that immunosuppression
achieves both, a significant reduction of parasitaemia and
a milder course of the disease.
Azathioprine could further affect parasitaemia and host
survival by directly affecting the survival and replication
of the pathogen or its ability to evade parasitized erythro-
cytes and to invade noninfected erythrocytes. Indeed,
higher concentrations of azathioprine decreased in vitro
parasitaemia and DNA/RNA content of parasitized eryth-
rocytes.
The effect of azathioprine could further be secondary to its
ability to stimulate suicidal death of erythrocytes [39], an
effect, which could contribute to or even account for the
blunted parasitaemia and the survival of the infected
mice. The drug could be effective by accelerated clearance
of infected erythrocytes due to eryptosis. Moreover, the
enhanced eryptosis may promote the release of pro-
inflammatory cytokines from activated macrophages,
thereby resulting in the activation of the hormonal stress
response [48].
Phosphatidylserine-exposing erythrocytes are engulfed by
macrophages [21,22] and thus cleared from circulating
blood [23]. A wide variety of further endogenous media-
tors and xenobiotics trigger eryptosis, including haemo-
lysin Kanagawa [49], listeriolysin [50], PGE2 [51], Bay-
5884 [52], platelet activating factor [53], chlorpromazine
[54], anandamide [55], methylglyoxal [56], paclitaxel
[57], curcumin [58] amyloid peptides [59], valinomycin
[60], aluminium [61], lead [62], mercury [63] and copper
ions [64]. Moreover, eryptosis is enhanced in a variety of
clinical conditions including iron deficiency [23], sickle-
cell anaemia [65,66], beta-thalassaemia [7], glucose-6-
phosphate dehydrogenase (G6PD)-deficiency [7], phos-
phate depletion [67], Haemolytic Uremic Syndrome [68],
sepsis [69], malaria [25] and Wilson disease [64]. Several
of those diseases and xenobiotics have already been
shown to favorably influence the course of malaria,
including sickle-cell trait, beta-thalassaemia-trait,
homozygous Hb-C and G6PD-deficiency [7,26-30], iron
deficiency [1], lead [2], chlorpromazine [31] and
cyclosporine [32]. Azathioprine may be a particularly
attractive substance for the treatment of malaria because it
is clinically widely used and thus ample knowledge has
been accumulated about its side effects. Nevertheless, fur-
ther eryptosis-inducing substances may be shown in near
future to be effective as antimalarial drugs.
Conclusion
In conclusion, azathioprine accelerates eryptosis of Plas-
modium-infected erythrocytes The effect contributes to or
even accounts for the favourable effect of azathioprine on
parasitaemia and survival of the host during malaria.
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